Will Death in French Drug Trial Lead to Tighter Phase 1 Rules?
While regulators are trying to figure out what went wrong, independent chemists have dug into the mechanism of what may have been a "dirty" drug.
6397 RESULTS
Sort By:
While regulators are trying to figure out what went wrong, independent chemists have dug into the mechanism of what may have been a "dirty" drug.
Preliminary data suggests a long lag between Aβ and tau deposits as the disease develops.
Scientists find evidence for an Aβ etiology distinct from Alzheimer’s after brain trauma.
Attendees grapple with conflicting binding results
AV1451 appears too weak to diagnose non-AD tauopathies.
Newly discovered Aβ effects of this cancer drug may be unrelated to its previously known mechanism of action.
A free, open online course on rare forms of Alzheimer’s, Lewy body, and frontotemporal dementia aims to spread knowledge while harnessing social learning.
Some repeats seem to interfere with regulation of translation, causing dendrites to shrink.
A new procedure turns circulating immune cells into neurons. It could simplify how scientists make patient-specific disease models.
Proteolysis of other substrates, including Neuregulin, proceeds apace.
Healthy neurons tell astrocytes how to act. In the case of ALS, astrocyte signals spell trouble.
Results raise the tentative prospect that a medical food might have possible cognitive benefit early in disease.
Studies of two new mouse models find that this mutation leads to excitotoxicity, but little protein aggregation.
Souvenaid Trial Missed Primary, Partially Met Secondary Endpoints New Tack on Aβ Oligomer Role in Disease and Treatment The 14th International Athens/Springfield Symposium on Advances in Alzheimer Therapy was held March 9 to 12 in Athens, Greece. Research
Study improves confidence in three core biomarkers and five emerging markers, most in cerebrospinal fluid and one in blood.